Sartorius Stedim Biotech DIM.PA · EUR
Health Care · Life Sciences Tools & Services · Euronext Paris · 🇫🇷 France
226.20
+0.18%
Close of 9 Nov 2026, in EUR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Sartorius Stedim Biotech
Its shares trade on Euronext Paris under the ticker DIM.PA. It has been listed since 20 October 1994. In the fiscal year to 31 December 2025, it reported revenue of €2.97bn and net income of €265.6m. At that date it held total assets of €8.02bn and shareholders' equity of €4.09bn.
Sartorius Stedim Biotech SA provides equipment and services for the development, quality assurance and production processes of the biopharmaceutical industry. The company is headquartered in Aubagne, Paca. The firm covers the segments of biotechnology and mechatronics. Sartorius provides services which help customers to implement complex and quality-critical processes in biopharmaceutical production and laboratory environments in a time- and cost-efficient way. The Company’s customers are from the biotech, pharma and food industries, as well as from public research institutes and laboratories. Sartorius operates its own production facilities in Europe, Asia and America, and also has sales offices and local representatives in more than 110 countries. The firm operates through its subsidiaries, including Sartorius Stedim Austria GmbH, Sartorius Stedim Plastics GmbH, BioOutsource Ltd and Wave Biotech AG, among others.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Listed since
- 20 Oct 1994
- Employees
- 7,566
Leadership
Pay as last reported
- Dr. Joachim KreuzburgExecutive Chairman of Board, since 2007€364,000
- Dr. Rene FaberChief Executive Officer, Executive Director, since 2019€1.2m
- Ms. Anne-Marie GraffinLead Non-Executive Independent Director€91,000
- Mrs. Romaine FernandesNon-Executive Director, Employee Representative
- Dr. Lothar KappichNon-Executive Director€84,000
- Ms. Cecile DussartIndependent Director
- Mr. Christopher NowersIndependent Director
- Ms. Pascale BoisselNon-Executive Independent Director€93,000
- Ms. Susan DexterNon-Executive Independent Director€84,000
- Ms. Petra KirchhoffHead of Corporate Communications and Investor Relations, since 2020
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 80
- Environment
- 99
- Social
- 99
- Governance
- 41
- Direct emissions (scope 1)
- 13,712 t
- Energy emissions (scope 2)
- 40,780 t
- Value chain emissions (scope 3)
- 527,796 t
- Women in the workforce
- 39.24856%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- With innovative product portfolio, Sartorius Stedim Biotech SA demonstrates technological superiority and a competitive edge in the market. The company's strong focus on research and development enables it to deliver cutting-edge solutions to its customers, ensuring customer satisfaction and loyalty.
- Sartorius Stedim Biotech SA boasts a vast global footprint through its extensive distribution network. This enables the company to effectively reach various markets worldwide, expanding its customer base and revenue streams.
Weaknesses
- Despite its strong presence in the market, Sartorius Stedim Biotech SA faces challenges related to limited diversification of its product offerings. This puts the company at risk of losing market share in case of technological advancements or changes in customer preferences.
- Sartorius Stedim Biotech SA's heavy reliance on external suppliers for key components of its products poses a potential vulnerability, as disruptions in the supply chain may impact production and delivery timelines.
Opportunities
- The rising demand for biopharmaceuticals presents a significant opportunity for Sartorius Stedim Biotech SA to capitalize on. The company can leverage its expertise in bioprocessing technologies to develop and offer specialized solutions that cater to this growing market.
- Expansion into emerging markets, such as Asia and Latin America, can provide Sartorius Stedim Biotech SA with new growth avenues. These markets offer untapped potential and can serve as a source of revenue diversification for the company.
Threats
- Intense competition in the biotech industry poses a threat to Sartorius Stedim Biotech SA. The presence of established players and new entrants constantly vying for market share may lead to price wars and margin pressures.
- Changing regulatory landscape and compliance requirements pose challenges for Sartorius Stedim Biotech SA. Ensuring adherence to evolving regulations and standards can be costly and time-consuming, potentially affecting the company's operations and profitability.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.